- 21 Sep 2017 KY1005 impressive in acute GVHD model
- 31 Jul 2017 Kymab's KY1005 antibody in clinical trial
- 29 Jul 2017 Allan Bradley at Canaccord Genuity Growth Conference
- 16 Jun 2017 Kymab appoints Dr Martin Nicklasson as Non-Executive Chair
- 9 May 2017 Sonia Quaratino appointed Kymab CMO
- 23 Jan 2017 Arndt Schottelius appointed Executive VP R&D
- 9 Jan 2017 Kymab expands Infectious Disease Programmes
- 5 Dec 2016 Antibody shows dramatic post-transplant benefit
- 24 Nov 2016 Kymab secures US$100 million Series C funding
- 8 Sep 2016 Kymab's early steps towards HIV vaccine